Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody (mAb), a Friday Hong Kong bourse filing said.
The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.
The biopharmaceutical firm and HBM (HKG:2142) in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.